Schedule 13G ownership disclosure

Aclaris Therapeutics Inc

Common Stock · CUSIP: 00461U105

Event date: 2025-03-31

Filing-level shares
4,970,254
Percent of class
4.60%
  • The Vanguard Group

    Shares: 4,970,254 · Class: 4.60%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000932471-25-000412
Form type
SCHEDULE 13G/A
Filer
Aclaris Therapeutics, Inc.
CIK
CIK 1557746
Filed
Apr 30, 2025
Reporting period
Mar 31, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub